Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Passage BIO, Inc.PASG · Entity 7829 | Chief Res. & Develop Officer | February 10, 2022 | February 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Passage BIO, Inc.
Report date February 10, 2022 · Filed February 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2032-02-09 | Direct | 157,500 |
Reported balance
After 2022-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-10 · Grant · Acquired 157,500 · Balance 157,500 F1: The stock option vests as to 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2022 Filed Feb 14, 2022 17:21 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantStock Option (right to buy) · Derivative | 157,500 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001787297-22-000005 · primary_doc.xml · derivative · entry 1 Salinas Eliseo Oreste · CIK 0001435756 · Chief Res. & Develop Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,500 Underlying: Common Stock · 157,500 shares Expires 2032-02-09 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 22, 2021 Filed Mar 29, 2021 19:01 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantRestricted Stock Unit (RSU) · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023476 · doc4.xml · derivative · entry 3 Salinas Eliseo Oreste · CIK 0001435756 · Chief Res. & Develop Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 1/4 of the RSUs will vest on June 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 1/4 of the RSUs will vest on June 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 22, 2021 Filed Mar 29, 2021 19:01 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantRestricted Stock Unit (RSU) · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023476 · doc4.xml · derivative · entry 2 Salinas Eliseo Oreste · CIK 0001435756 · Chief Res. & Develop Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs shall vest as to 33.33% of the total shares each on June 15, 2021, September 15, 2021 and December 15, 2021, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs shall vest as to 33.33% of the total shares each on June 15, 2021, September 15, 2021 and December 15, 2021, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 22, 2021 Filed Mar 29, 2021 19:01 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (Right to buy) · Derivative | 275,000 | $0.00 Strike: $18.85 | $0.00 |
DisclosureSEC source: 0001209191-21-023476 · doc4.xml · derivative · entry 1 Salinas Eliseo Oreste · CIK 0001435756 · Chief Res. & Develop Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-03-22 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on March 22, 2022, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on March 22, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.